








   
ABSTRACT 
Objective: The aim of this study was to synthesise and evaluate polylysine-based effectors for pretargeted radioimmunotherapy and imaging. These 
molecules can readily be size-modified and charge-modified to decrease the renal uptake of radioactivity, which is often a major problem for small 
radiolabeled molecules. Several chelators and biotin molecules (for antibody-streptavidin-binding in vivo) are also easily incorporated into one 
structure because of the polylysine.  
Methods: The effectors were synthesised using poly-L-lysine, NHS-LC-biotin, CHX-A’’-DTPA or p-SCN-Bn-DOTA and succinic anhydride. They were 
characterised, labelled with 
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213Bi for targeted α therapy, 68Ga for PET and 111In for SPECT, and evaluated in vitro. A kidney uptake study was 
performed as well with two different-sized 213Bi-labeled effectors, to evaluate how the difference in size affects the renal filtration. 
Results: Radiochemical purities between 97.4±0.6 % and 99.6±0.1 % and decay-corrected yields of 80.2±2.4 % after purification were achieved 
with the radiolabeled molecules, as well as a specific activity of 7.6 × 103
Keywords: Pretargeting, Radiometals, Polylysine, Radioimmunotherapy, Radioimmunoimaging, Kidney 
GBq/µmol. The avidin binding capacity was 94.4±1.9%. The kidney uptake 
study demonstrated a reduction of renal absorbed dose by 80% when modifying the molecular size and charge. 
Conclusion: The synthesised polylysine-based effectors show potential for further in vivo evaluation in pretargeted radioimmunotherapy and imaging.  




In radioimmunotherapy (RIT), tumor-specific antibodies are labelled 
with cytotoxic radionuclides. RIT has shown high potential as an 
adjuvant treatment in many types of malignancies [1-3]. However, a 
limitation of treatments with radiolabeled antibodies is that they 
typically require several hours after intravenous (i. v.) injection to 
localise the tumour cells. The main reason for the slow diffusion and 
tumour cell uptake in vivo is the large size of antibodies (150 kDa). The 
slow targeting process in RIT is an obstacle, particularly when employing 
short-lived radionuclides such as bismuth-213 (213
In order to circumvent this drawback in RIT, pretargeted radio-
immunotherapy (pRIT) has been developed [
Bi; t1/2 = 45.6 min).  
4-6]. pRIT is a strategy to 
decrease the required time for the radioactive complex to find the 
tumor sites. In many situations, the decreased distribution time in 
pRIT reduces the activity uptake in normal tissue, leading to an 
expansion of the therapeutic window. In pRIT, administration of the 
treatment is separated into two steps. First, the pretargeting molecule 
(often an antibody conjugate) is administered to localise and bind to 
the tumor cells. When a maximum amount of pretargeting molecules is 
bound to the tumors, an effector with high affinity for the pretargeting 
molecule should be administered. The effector is a radiolabeled 
molecule of very small size compared with antibodies, which gives it a 
rapid in vivo distribution. The high affinity and small size of the 
effector result in much faster radionuclide uptake in tumors in pRIT 
than is achievable in conventional RIT [7]. Additionally, the small 
effector molecule can more rapidly distribute within the tumor, 
resulting in more uniform activity distribution in the tumor for pRIT 
compared with RIT [8]. Fast and uniform intratumoral distribution can 
be crucial for efficient treatment, particularly when using short-lived 
radionuclides which emit short path length radiation, e. g., the α-
emitter 213
The advantages of pRIT are also applicable for imaging purposes. 
Pretargeted radioimmuno imaging (pRII) has the potential to detect 
smaller tumors than is possible with conventional imaging methods. The 
small effector results in rapid activity uptake in the tumor, as well as 
rapid blood clearance. This can lead to a high tumor-to-background ratio 
and dramatic reduction of non-target radiation doses to patients [
Bi. 
9]. In 
addition, pRII enables short-lived radionuclides suitable for imaging, e. g., 
flourine-18 (18F; t1/2 = 109.8 min) and gallium-68 (68
Generally, effectors for labelling with metal radionuclides are based on 
derivatives from a chelator, e. g., DOTA and DTPA, and biotin [
Ga; t1/2 = 67.6 
min), to be used with tumor-specific antibodies. 
7,10,4-
6]. However, a disadvantage of using e. g., DOTA-biotin is that it results 
in a relatively high radiation dose to the kidneys. Additionally, it is 
difficult to achieve very high specific activity with these molecules. 
Therefore, the aim of this study was to synthesise and evaluate an 
effector based on a poly-L-lysine scaffold. There are several 
advantages of using a polylysine backbone. i.) Each effector molecule 
can incorporate several biotin groups and several radionuclides 
binding sites (in this case, several chelators). In this way, the avidity 
between the effector and the pretargeting molecule can be increased. 
Furthermore, by incorporating more chelators in the effector 
molecule, a higher specific activity is achievable. An increase in avidity 
and in specific activity can lead to an increased activity accumulation 
in the tumors. ii.) Variation of the molecular size becomes effortless, 
which should provide opportunities to optimise the biodistribution 
because of size-dependent renal filtration [11]. Thus, it can potentially 
decrease the radiation dose to the kidneys, which is often the dose-
limiting organ for small radiolabeled molecules. iii.) Variation of the 
overall charge of the molecule becomes effortless. Since not only 
molecular size, but also charge influences the renal handling [11], the 
ability to vary charge also provides opportunities to optimize the 
biodistribution. Polylysine has formerly been used as a multicarrier in 
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pretargeting as well as in other contexts in the field of targeted 
radionuclide therapy [12-15].  
The hypotheses in this study were that polylysine-based effectors are 
easily synthesised and radiolabeled with a high specific activity that 
the effectors have a high avidity for streptavidin if conjugated with 
biotin and that radioactivity uptake in the kidneys can be altered when 
changing the size of the polylysine scaffold. The performed analyses 
indicate if polylysine-based effectors prospectively can increase 
tumour dose relative to normal tissue dose in future in vivo evaluation 
of pRIT and pRII, relative to more common effectors. In order to test 
our hypotheses, poly-L-lysine was conjugated with p-SCN-Bn-DOTA or 
CHX-A´´-DTPA to make the molecules suitable for labelling with a 
variety of radiometals. They were also conjugated with biotin, which 
enables employment of any streptavidin-conjugated pretargeting 
molecule. The synthesised effectors were analysed for composition 
and purity after synthesis. Subsequently, the effectors were labelled 
with 213Bi for future use in α therapy, 68Ga for use in positron emission 
tomography (PET) and indium-111 (111In) for single-photon emission 
computed tomography (SPECT). The radiolabeled effectors were 
analysed for radiochemical purity and tested for avidin binding 
capacity. A kidney uptake study in mice with two different-sized 
effectors labelled with 213Bi was performed as well, to see if moderate 
changes in molecular size would affect the renal uptake. 
MATERIALS AND METHODS 
Radionuclides 
213Bi was produced by a 225Ac/213
16
Bi generator (Institute for 
Transuranium Elements (ITU), Karlsruhe, Germany) as described 
previously [ , 17], and eluted according to the ITU standard protocol. 
Briefly, 600 μl of a 0.1 M HCl/0.1 M NaI solution was run through the 
generator column to elute the 213Bi. The pH of the eluate was adjusted 
to 5.3–5.5 with a 20% w/w L-ascorbic acid solution and 4 M sodium 
acetate. 68Ga was produced by a 68Ge/68Ga generator (Eckert and 
Ziegler Radiopharma GmbH, Berlin, Germany). The generator was 
eluted with 0.1 M HCl using an automated module (Eckert and Ziegler 
Radiopharma GmbH), and the pH of the eluate of 68Ga was adjusted to 
5.3-5.5 in the same way as for the 213Bi. The decay chains of the 
225Ac/213Bi generator and the 68Ge/68Ga generator used in this study 
are shown in fig. 1. 111In was purchased as a solution of 111InCl3 
(Covidien Sverige AB, Solna, Sweden). The pH of the 111InCl3
 
Fig. 1: Decay chains of the 
 solution 
was adjusted to 5.3-5.5 with 2 M ammonium acetate. 
 
225Ac/213Bi generator and the 
68Ge/68
Female BALB/c (nu/nu) mice (Charles River Laboratories 
International, Wilmington, MA, USA) were used in the in vivo 
experiments. The mice were housed at 22 °C in 50–60% humidity 
with a light/dark cycle of 12 h. The animals were kept under 
pathogen-free conditions and were given standard autoclaved food 
pellets, except for the 4 d before the experiment when they were 
given biotin-free food pellets. The mice were given water ad libitum. 
The animal experiments were approved by the Ethics Committee at 
the University of Gothenburg (approval number: 89-2014). 
Synthesis of the CHX-A’’-DTPA-conjugated effector 
The effectors were essentially produced in the same way as in 
previously reported studies of effectors used for astatine-211 
(
Ga generator used in the study. Decay modes and half-
lives of the radionuclides are indicated 
 
Animals 
211At)-labelling, [12, 18] except for that chelators were attached to 
the polylysine instead of astatine-binding residues. Poly-L-lysine of 
high purity (98.5%) and well defined size of 30 or 50 lysine residues 
(Caslo ApS, Lyngby, Denmark) was dissolved to a concentration of 2 
mg/ml in 0.2 M carbonate buffer, pH ~8.5, which had been filtered 
through Chelex 100 resin (Bio-Rad Laboratories, Hercules, CA, USA). 
Firstly, NHS-LC-biotin (Nordic Biolabs AB, Täby, Sweden) in DMSO 
(12 mg/ml; 0.026 M) was added to the poly-L-lysine in 5 x molar 
excess and the reaction proceeded for 30 min at room temperature 
(RT). Secondly, a solution of 0.02 M of CHX-A’’-DTPA in DMSO was 
added to the biotin-poly-L-lysine in 10 x molar excess and the 
reaction proceeded overnight at RT. The molecule was subsequently 
charge-modified with succinic anhydride, which was added in ~50 x 
molar excess relative to the ε-amino groups. The charge modification 
proceeded for 20-30 min while the pH was kept constant at ~8.5 by 
repeated addition of 1 M Na2CO3
To analyse the number of free amino groups per molecule, 2,4,6-
trinitrobenzene sulfonic acid (TNBS; G-Biosciences, St. Louis, MO, 
USA) was used [19]. Through this analysis, the number of biotin 
residues on each effector molecule was determined by measuring 
the amount of free amino groups left after the reaction between the 
polylysine and the biotin. The analysis was performed according to 
the G-Biosciences standard protocol. Briefly, TNBS was added to 
~10 µg of the peptide, and the samples and standards were 
incubated for 2 h at 37 °C. Subsequently, spectrophotometry was 
used to evaluate the absorbance of the samples at 335 nm, which 
correlates to the number of free amines. The degree of succinylation 
for charge modification was analysed with TNBS in the same way. 
The number of chelators on the effectors was assessed by an 
arsenazo III (Sigma-Aldrich Sweden AB, Stockholm, Sweden) 
spectrophotometric assay [
.  
Purification of the CHX-A’’-DTPA-conjugated effector 
Prior to the labelling, the effector molecule was purified and the 
buffer was exchanged to Chelex-filtered 0.1 M ammonium acetate, 
pH 5.2, or 0.1 M citrate, pH 5.5, using a 3-K Microsep Centrifugal 
Device (PALL Life Sciences, Ann Arbor, MI, USA). The reaction 
solution was centrifuged at 1680 x g until 10 ml of buffer had run 
through the filter and a concentration of 0.6 mg/ml of the effector 
molecule remained. The approximate size and concentration, as well 
as the purity of the produced effector molecule, was evaluated by 
size exclusion fast protein liquid chromatography (FPLC) using a 
Superdex-200 column and an ÄKTA FPLC system (GE Healthcare, 
Uppsala, Sweden). In order to evaluate the molar absorptivity (ε) of 
the effector molecule at 225 nm, a standard curve with solutions of a 
unpurified effector molecule (with known concentrations) was 
made. Solutions were diluted to different concentrations in the 
range of the final sample concentration and subsequently analysed 
by FPLC. The standard curve was produced from sample peaks in the 
chromatograms obtained from the FPLC analysis. The concentration 
of the purified effector molecule in the product solution was then 
evaluated using the standard curve. 
Synthesis and purification of the DOTA-conjugated effector 
The DOTA-conjugated effector was produced and purified in the 
same way as the CHX-A’’-DTPA-conjugated effector, with the 
exception that 5, 10, or 15 x molar excess of p-SCN-Bn-DOTA was 
added to the biotinylated poly-L-lysine.  
The syntheses of the CHX-A’’-DTPA-and DOTA-conjugated effectors 
are illustrated in fig. 2 and fig. 3. 
Analysis of effector molecule composition 
20]. 
Lindegren et al. 




Fig. 2: Synthesis of CHX-A’’-DTPA-conjugated effector. Poly-L-lysine (a.) is reacted with NHS-LC-biotin (b.) and CHX-A’’-DTPA (c.), and 
subsequently charge-modified with succinic anhydride (d.) to produce the effector (e.) 
 
 
Fig. 3: Synthesis of the DOTA-conjugated effector. Poly-L-lysine (a.) is reacted with NHS-LC-biotin (b.) and p-SCN-Bn-DOTA (c.), and then 
charge-modified with succinic anhydride (d.) to produce the effector (e.) 
Lindegren et al. 
Int J Pharm Pharm Sci, Vol 9, Issue 1, 87-93 
 
90 
Labelling with 213Bi 
The labelling was essentially performed as previously reported [21]. 
The 213Bi-labelling of the effector molecules was performed in the 
pH-adjusted generator eluate (described under section 
“Radionuclides”) by adding 12 µg of the effector to the eluate. When 
labelling the CHX-A’’-DTPA-conjugated effector molecules, the 
reaction was conducted with vigorous agitation for 5 min at RT. In 
contrast, when labelling the DOTA-conjugated effector molecules, 
the reaction proceeded for 5 min at 95 °C in a water bath. To 
terminate the labelling reactions, the reaction solutions were 
quenched with 10 μl of 1.5 mg/ml DTPA. After cooling down to RT, 
purification and buffer exchanged into phosphate-buffered saline 
(PBS) were performed using a PD-10 column (GE Healthcare, 
Buckinghamshire, UK). The labelling yield directly after synthesis, as 
well as radiochemical purity (RCP) after purification, was analysed 
by instant thin layer chromatography (ITLC; PALL Life Sciences) 
using 0.1 M citrate buffer, pH 5.5, as the mobile phase.  
Labelling with 68Ga 
18 µg of DOTA-conjugated effector molecule produced with 10 x 
molar excess of p-SCN-Bn-DOTA was added to the pH-adjusted 
generator eluate (described under section “Radionuclides”). The 
labelling and subsequent purification/buffer exchange steps were 
performed in the same way as described in the 213Bi-labelling 
section. RCP was analysed by ITLC with 0.1 M citrate buffer, pH 5.5, 
as the mobile phase.  
Labelling with 111In 
12 µg of CHX-A’’-DTPA-conjugated effector molecule was added to 
the pH-adjusted 111InCl3
To evaluate the avidin binding capacity of the effectors, an analysis 
was essentially performed as reported previously [22]. 50 µl of 
avidin-linked agarose beads (Thermo Fisher Scientific, Rockford, IL, 
USA) were added to each of 3 microcentrifuge filter tubes (Corning 
Costar Spin-X; Sigma-Aldrich Sweden AB, Stockholm, Sweden), and 
the tubes were centrifuged for 1 min at 503 x g. In addition, 100 µl of 
PBS and 30 ng of labelled effector were added to the filter tubes. As 
controls, 100 µl of PBS were added to 3 empty filter tubes. The 
samples and controls were incubated for 1 h at RT with gentle 
agitation. The tubes were centrifuged for 1 min at 503 x g, and the 
filters were washed twice with PBS. The filters were extracted from 
the tubes and measured in a γ counter (Wizard 1480, PerkinElmer, 
Waltham, MA, USA) and the avidin binding capacity was determined 
as bead-associated activity divided by total applied activity. 
 solution. The labelling reaction proceeded 
for 10 min with vigorous agitation, and the reaction was quenched 
with 10 μl of 1.5 mg/ml DTPA. Purification and buffer exchange into 
PBS were performed using an NAP-5 column (GE Healthcare, 
Buckinghamshire, UK). RCP was analysed by ITLC with 0.1 M citrate 
buffer, pH 5.5, as the mobile phase. 
Avidin binding capacity 
Specific activity 
Experiments were performed to evaluate the possibility to increase 
the specific activity with increasing amounts of chelators 
incorporated in the effector molecule. Decreasing amounts, as low as 
120 ng, of effector conjugated with either 5 or 15 x molar excess of 
chelator were labelled with equal amounts of 213
Renal uptake 
Bi. Consequently, 
the effect of the amount of chelator bound to the effector when the 
specific activity is increased was measured. When lower amounts of 
effector molecule were labelled, the reaction tube was first coated 
with 1-% bovine serum albumin in PBS to prevent adsorption of the 
effector to the walls of the reaction tube. 
The renal uptake was evaluated in mice for 213Bi-labeled effectors of 
2 different sizes. The mice were subcutaneously inoculated with 
1.25×107 human ovarian cancer cells (OVCAR-3) 1 mo prior to the 
experiment. All mice were given DMPS (sodium 2,3-
dimercaptopropane-sulfonate monohydrate; 1.2 mg/ml) in the 
drinking water 24 h before injection of radioactivity to reduce 
kidney uptake further. All mice were also given streptavidin-MX35 
antibodies (60 µg) at the same time point. Poly-L-lysine with the size 
of 30 or 50 L-lysine residues were reacted with 5 x molar excess of 
NHS-LC-biotin and 10 x molar excess of CHX-A’’-DTPA, and then 
completely succinylated to obtain a maximum negative net charge. 
The polylysine-based effectors were subsequently labeled with 213Bi 
(RCP: 98.4% and 98.8%, respectively). 12 mice were injected i. v. 
with around 1.0 MBq of the labeled effector based on 30 lysines in 
100 µl PBS and 12 mice were injected i. v. with around 1.0 MBq of 
the labeled effector based on 50 lysines in 100 µl PBS. The animals 
were sacrificed to monitor tissue uptake 15 min, 45 min, 90 min and 
180 min post injection, i.e., when up to 94% of the 213
 
Bi had decayed. 
  
Fig. 4: FPLC chromatograms are showing the UV absorbance at 225 nm. PBS was used as mobile phase, and the samples were purified 
using a 3-K Microsep Centrifugal Device with ~20 ml of PBS. The peaks in the chromatograms show the polylysine-based effector 
conjugated with a.) 10 × molar excess of CHX-A’’-DTPA, b.) 5 × molar excess of DOTA, c.) 10 × molar excess of DOTA and d.) 15 × molar 
excess of DOTA 
Lindegren et al. 




Analysis of effector molecule composition 
The number of biotin residues on each polylysine was evaluated by 
measuring the number of free amines on the polylysine after reaction 
with the amine-reactive biotin. The evaluation of a number of free 
amines was performed by reaction with TNBS. After the reaction of poly-
L-lysine with NHS-LC-biotin, 85.1% of the amino groups were still free 
according to the TNBS analysis. Consequently, the effector had an 
average of 4 biotin residues attached. After reaction of the biotinylated 
polylysine with 5, 10, and 15 x molar excess of the chelator, the arsenazo 
III spectrophotometric assay showed that 5, 9, and 13 chelators, 
respectively, were attached to the effector molecule. Finally, the analysis 
of the charge modification showed complete succinylation of the effector, 
thus achieving maximum negative net charge. This is theoretically of 
advantage for decreasing the renal uptake.  
Size exclusion fast protein liquid chromatography (FPLC) 
As seen in fig. 4, the FPLC chromatograms indicate almost 
completely pure polylysine-based effectors after synthesis and 
purification. Minimal peaks can be seen on the right side of the 
product peaks which could be, e. g., small rests of unbound chelator 
(fig. 4). A small “shoulder” can also be seen on the left side of the 
peaks in c.) and d.), which could possibly be a small amount of 
aggregated product. Since the likely impurities, in this case, would 
absorb UV at the short wavelength of 225 nm, no other impurities in 
the product samples were expected. 
Labelling with 213Bi, 68Ga and 111
The labelling results are shown in table 1. The radiochemical yield 
(RCY) after purification of all compounds varied over a narrow 
range of 57-65.5%, with the exception of 
In 
111In-labeled effector, 
which was about one-third higher. Since the RCY is not decay-
corrected, the longer half-life of 111In (t1/2 = 2.80 d) compared with 
213Bi (t1/2 = 45.6 min) and 68Ga (t1/2 = 67.6 min) explains this. The 
decay-corrected yields of all compounds remained high, 80.2±2.4% 
(mean±SD). Radiochemical purities (RCP) were very high for all 
three radionuclides after labelling and subsequent purification. 
When labelling the CHX-A’’-DTPA-conjugated effector molecule with 
213Bi, the RCP was 97. 4±0.6%, while all the other RCP values were 
over 99%, approaching unity, with values as high as 99.6±0.2%, as 
determined by ITLC. The yield after labelling was determined by 
ITLC from the crude reaction mixture before purification, at the end 
of the synthesis. The CHX-A’’-DTPA-conjugated effector molecule 
had a labelling yield of 94.0±0.6%. The labelling yield of the 213Bi-
labeled DOTA-conjugated effector molecules was 98.8±0.2%. 
 
Table 1: Results after labelling the effectors with 213Bi, 68Ga and 111
Radionuclide (Amount of chelator in the effector synthesis) 
In. RCY = radiochemical yield, RCP = radiochemical purity. The 
standard deviation (SD) is included when three or more analyses were performed 
RCY (%) Decay-corrected yield (%) RCP (mean value±SD (%)) 
213 61.0-61.8 Bi (CHX-A’’-DTPA*10) 77.8-81.9 97.4±0.6 
213 57.1-57.6 Bi (DOTA*5) 77.4-80.4 99.1±0.1 
213 62.7 Bi (DOTA*10) 83.8 99.2±0.1 
213 57.1-57.6 Bi (DOTA*15) 77.4-80.4 99.6±0.2 
68 65.5 Ga (DOTA*10) 79.6 99.1±0.1 
111 83.3 In (CHX-A’’-DTPA*10) 83.3 99.2 
 
Avidin binding capacity 
The avidin binding capacity of the CHX-A’’-DTPA-conjugated effector 
molecule was 92.4±0.7%. The avidin binding capacity of the DOTA-
conjugated effector molecule reacted with 5 x and 15 x molar excess 
of DOTA was 93.2±1.7% and 94.9±0.2%, respectively. 
Specific activity 
After labelling 120 ng of effector produced with 5 x molar excess of 
DOTA, the RCP was 82.3% without purification and buffer exchange. 
The labelling was performed with 86.0 MBq 213Bi, and the reaction 
was finished 14 min after elution. The specific activity was 
5.0×103GBq/µmol at the end of the labelling reaction, corresponding 
to 1 in 31 effector molecules labeled with 213Bi. In contrast, when 
labelling 120 ng of effector produced with 15 x molar excess of 
DOTA, the RCP was 96.4% without purification and buffer exchange. 
The labelling was performed with 83.2 MBq 213Bi, and the reaction 
was completed 14 min after elution. The product exhibited a specific 
activity of 7.6×103GBq/µmol at the end of the labelling reaction, 
corresponding to 1 in 20 effector molecules labeled with 213Bi. The 
same procedure was performed with effectors synthesized with 5 or 
15 x molar excess of CHX-A’’-DTPA. 120 ng of effector produced with 
5 or 15 x molar excess of CHX-A’’-DTPA were labeled with 11.2 MBq 
and 12.4 MBq, respectively, and the labelling reactions were finished 
9 min after 213Bi elution. The RCP values were 70.9% and 82.5%, 
which correspond to a specific activity of 6.1×102GBq/µmol for the 
effector produced with 5 x molar excess of CHX-A’’-DTPA, and a 
specific activity of 1.1×103
The differences in renal uptake of the polylysine-based effector with 
a 30 lysine scaffold (total MW: 14 kDa) and the polylysine-based 
effector with a 50 lysine scaffold (total MW: 19 kDa) are shown in 
fig. 6. The molecule of larger size, and in this case more negative net 
charge, has an average kidney uptake of approximately 1/4, 
compared with the smaller-sized molecule during the period of time 
the evaluation was performed (up to 3 h post injection). 
 
GBq/µmol for the effector produced with 
15 x molar excess of CHX-A’’-DTPA. The difference in specific activity 
achieved with different amounts of chelator attached to the effector 
is illustrated in fig. 5. 
Renal uptake 
 
Fig. 5: Higher specific activity was achieved with a higher 
number of chelators bound to the effector 
Lindegren et al. 




Fig. 6: Radioactivity uptake in the kidney of effectors of two 
different sizes (14 kDa and 19 kDa). n = 3 for each time point. 
Tissue concentration of radioactivity is expressed as a 
percentage of injected activity per gram (% IA/g). Means and 
standard error of the mean (SEM; error bars) are depicted 
 
The area under the curves (AUCs) of the time-activity curves (TACs; 
i.e. the non-decay-corrected % IA/g values) were calculated as well, 
as an estimation of the absorbed dose to the kidneys for the two 
different 213Bi-labeled effectors. According to the AUCs, the 14 kDa 
effector results in 5 times higher absorbed dose to the kidneys, 
compared with the 19 kDa effector.  
Statistical analysis 
A statistical analysis was performed to evaluate if there was a 
significant difference between the two groups in the renal uptake 
study, using an unpaired two sample t-test. Since the variance was 
higher in the group receiving the 14 kDa effector, a variance 
stabilizing transformation of the data was performed prior to the t-
test. The unpaired t-test revealed a significant difference between 
the two groups at the first 3 time points (p-values = 0.0002–0.0041). 
However, at the last time point, the p-value was 0.0259, which is not 
significant with a significance level of 0.05/4, which should be used 
when taking the multiple testing into account. 
DISCUSSION 
Pretargeted radioimmunotherapy (pRIT) and pretargeted radio-
immunoimaging (pRII) are promising strategies to overcome some 
of the obstacles in conventional RIT and RII. Pretargeting strategies 
have been shown to result in faster distribution in vivo than RIT and 
RII, and a higher and more homogenous tumor uptake of 
radioactivity. Because of the more favourable pharmacokinetics, 
pretargeting is particularly useful when employing short-lived 
radionuclides such as 213Bi and 68
The radiochemical purity was high in the labelling experiments, and 
the radiochemical yield was 94-99% even before purification and 
buffer exchange. This verifies excellent labelling efficacies of the 
effectors and could make kit preparation possible. The quantity of 
chelator was shown to be important to obtain the highest specific 
activity possible; a maximum specific activity of 7.6×10
Ga.  
In the current study, poly-L-lysine-based effectors for pRIT and pRII 
were synthesised and evaluated. The poly-L-lysine scaffold enables 
several chelators and several biotins to be attached to each 
molecule, enabling a higher specific activity and increasing the 
avidity for streptavidin-conjugated antibodies. In addition, the size 
and charge of the polylysine-based effector can readily be varied, 
which is advantageous for optimising its biodistribution. Hence, the 
purpose of using this molecule is to offer a simple tool for optimizing 
tumour uptake relative to uptake insensitive normal tissues. 
Thereby, the therapeutic/diagnostic window could be improved. 
3GBq/µmol 
was achieved with the largest amount of DOTA attached to the 
effector when labelling with 213
Kidney uptake was reduced to approximately 1/4 when changing 
the molecular size of the effector from 14 kDa to 19 kDa. 
Consequently, the absorbed dose was reduced to 1/5 using the 
larger effector. The large difference in kidney uptake between the 
two relatively similar sizes of the effectors was surprising for us, and 
the reduction of kidney uptake demonstrated in this study could also 
be important for the development of other radiopharmaceuticals. 
The increased size of the effector consequently increased the 
negative net charge of the molecule, since more negative succinyl 
groups were incorporated into the larger molecule. Thus, by size and 
charge modification of an effector molecule, the renal uptake can be 
decreased and the critical radiation dose to the kidneys can be 
mitigated. This is important since the kidneys are often the dose 
limiting organs for small radiolabeled molecules. Studies have 
previously been performed with polylysine-based molecules of 
different size labeled with 
Bi. This is, to our knowledge, not 
achievable with conventional effectors, e. g., DOTA-biotin. However, 
when determining the best molar ratio between the polylysine and 
the chelator, one must take into account that although an increased 
number of chelators give higher specific activity, it also changes the 
shape, size, and hydrophobicity of the effector. These variations in 
the physical properties will likely affect its biodistribution. Thus, the 
optimum amount of chelator bound to the effector molecule must be 
evaluated in vivo (as well as the optimum amount of the other 
groups incorporated in the effector molecule).  
211 Lindegren 
et al. [12
At [12, 18, 23]. The study by 
] showed a decreasing kidney dose when increasing the size 
of the effector from 13 kDa to 386 kDa. However, a larger size may 
also decelerate the tumor uptake and increase whole body retention, 
thus underlining the importance of defining the optimum size. 
Furthermore, the charge selectivity of the glomerular barrier in the 
kidneys can affect renal uptake as well. That is, for molecules of the 
same size and shape, the more negatively charged ones are 
restricted from filtration to a greater extent [11]. Therefore, charge 
alterations by succinylation could be an additional tool for 
optimisation of tumor dose relative to kidney dose [24-26].  
The biotin-conjugated effector molecules presented here are intended to 
target streptavidin-conjugated antibodies. A disadvantage of using 
streptavidin is the potential problem of immunogenicity, which may 
hamper fractionated multiple treatments. This problem can be mitigated 
by mutating surface residues of streptavidin that are prone to elicit an 
immune response [27]. Another approach to deal with the 
immunogenicity of streptavidin is to employ other pretargeting systems, 
e. g., systems using trans-cyclooctene (TCO) and tetrazine [28, 9, 29]. 
Polylysine-based effectors can equally well be used in TCO-tetrazine 
pretargeting systems as in systems employing streptavidin and biotin. 
A limitation of the study is the analysis of the effector molecule 
structure. However, more conventional structure analyses such as 
mass spectrometry and NMR would be difficult since the synthesis 
does not render one defined molecule. That is, with this method of 
synthesis, a small range of different amounts of biotin and chelator 
attached to the effector is inevitably obtained. 
CONCLUSION 
Polylysine-based effector molecules suitable for pretargeted 
radioimmunotherapy (pRIT) and pretargeted radio immunoimaging 
(pRII) were successfully synthesised in this study. The polylysine 
makes a variation in molecular size and charge simple, and enables 
an increase in specific activity and avidity to streptavidin-conjugated 
pretargeting molecules. Radiolabelling of the effector molecule was 
demonstrated with 213Bi, 68Ga, and 111
We would like to thank Elin Cederkrantz, Lars Jacobsson, and Ragnar 
Hultborn for general help and support in this work. We would also 
like to thank Oleksiy Itsenko and Jakobina Grétarsdottir for 
providing us with 
In, which are important 
radionuclides suitable for therapy and imaging. The labelling 
experiments resulted in high radiochemical purity and yield, the 
avidin binding capacity of the effector molecules was over 90%, and 
the absorbed dose to the kidneys could be reduced to 1/5 when 
increasing the molecular size of the effector from 14 kDa to 19 kDa. 
In conclusion, these results show high potential for further 
investigations of polylysine-based effectors in preclinical trials 
evaluating treatment and imaging of different types of cancer.  
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